CA
NZ
UK
AU
IND
US
Spruce Biosciences (NASDAQ: SPRB) has appointed Adrian Quartel, M.D. FFPM, as its new Chief Medical Officer, bringing substantial rare disease and clinical development expertise to the biopharmaceutical firm. This strategic leadership adjustment sees Dr. Quartel taking over from Dr.
OPKO Health (NASDAQ: OPK) delivered earnings per share of -$0.01 for the quarter ended June 30 2026, surpassing the consensus estimate. Revenue expanded to $163.5 million, while operating loss narrowed to $7.0 million, a notable improvement from a $60.0 million loss a year earlier. …
ProMIS Neurosciences Inc. has revealed encouraging interim results from its Phase 1b clinical trial for PMN310, an innovative treatment targeting Alzheimer’s disease. Over a six-month evaluation period, the trial demonstrated no brain swelling cases, a finding important for ensuring safety in Alzheimer’s therapies. The …
EUDA Health Holdings Ltd. has entered into a Memorandum of Understanding (MOU) aimed at developing innovative stem cell therapies for cancer treatment. This strategic collaboration with GO POSB Organoids and Shenzhen Inno marks a significant step for EUDA as it seeks to bolster its …
GeoVax Labs, Inc. The clinical‑stage biotechnology firm also reported earnings per share of $-0.97, substantially better than the $-2.94 consensus estimate. This performance arrives as the company advances its core development programs, including the GEO‑MVA vaccine and the Gedeptin immuno‑oncology therapy.
Johnson & Johnson (NYSE: JNJ) has proposed a $5.5 billion comprehensive settlement to resolve its ongoing talc litigation, which has faced significant scrutiny over the years. This initiative follows a favorable ruling from the federal Multi-District Litigation (MDL) court, where judges indicated that plaintiffs …
MapLight Therapeutics, Inc. (NASDAQ: MPLT) faces significant pressure in the market, with insider officers having liquidated shares worth $6.7 million over the past two months. This selling activity, taking place across 21 transactions, raises concerns about the sentiment from current management amid a challenging …
Erasca, Inc. stands in the spotlight as it faces a class action securities lawsuit with a significant deadline looming on August 10, 2026. The case targets investors who purchased shares within the time frame of January 14, 2025, to April 26, 2026, accusing the …
GE HealthCare Technologies Inc. (GEHC) posted second-quarter earnings that fell short of analysts' expectations, reporting an earnings per share (EPS) of $0.99 against a consensus estimate of $1.07. While the figure marks a setback, the company's share price climbed 1.8% to $61.68, a noteworthy …
Argenx Announces $2.2bn Cash Deal for Forte Biosciences
Please wait processing your request...